Experimental daily pill may lower cholesterol in patients who don’t see enough benefit with statins alone, study finds

Merck's experimental oral PCSK9 inhibitor, enlicitide, demonstrated significant efficacy in Phase 3 trials, achieving up to a 60% reduction in LDL cholesterol when added to statin therapy for patients with elevated LDL and cardiovascular risk. This positions enlicitide as the first oral PCSK9 inhibitor to complete Phase 3, offering a potential oral alternative to existing injectable treatments and addressing a substantial unmet need for patients whose cholesterol is not adequately controlled by statins alone. Merck plans to seek FDA approval early next year, which could significantly expand the market for advanced lipid-lowering therapies.

Analysis

Merck's experimental oral PCSK9 inhibitor, enlicitide, demonstrated significant efficacy in Phase 3 trials, achieving up to a 60% reduction in LDL cholesterol over 24 weeks when added to statin therapy. This addresses a critical unmet need for the 70% of patients who do not reach guideline-directed cholesterol goals with existing lipid-lowering therapies alone. The trial, involving 2,912 high-risk adults, also showed sustained reductions through 52 weeks and improvements in other key lipid markers like ApoB and lipoprotein(a).

Enlicitide's oral administration represents a significant differentiator, as current PCSK9 inhibitors on the market are injectables, potentially offering a more patient-preferred option. Merck plans to submit for US FDA approval early next year, positioning enlicitide as the first oral PCSK9 inhibitor to complete Phase 3 trials. This could expand access and adherence for patients requiring advanced cholesterol management beyond statins.

The drug exhibited a favorable safety profile, with serious adverse events balanced between the enlicitide (10%) and placebo (12%) arms, and no particular adverse event standing out as imbalanced. This robust clinical data, coupled with the oral formulation, suggests a substantial market opportunity for Merck (MRK) in the cardiovascular disease space, which remains the leading cause of death in the US. The positive sentiment and high market impact score reflect the potential for this product launch.

Key Decisions for Investors

• Evaluate Merck's (MRK) valuation considering the significant revenue potential from enlicitide, given its strong efficacy, favorable safety profile, and first-in-class oral PCSK9 inhibitor status.
• Monitor the FDA approval timeline and any potential fast-track designations, as early market entry for this differentiated product could accelerate revenue generation.
• Assess the competitive landscape and patient adoption rates post-launch, particularly how the oral formulation impacts market penetration against established injectable PCSK9 inhibitors.